Roflumilast is safe and effective in improving symptoms and lung function in severe COPD

https://doi.org/10.4081/monaldi.2013.28

Authors

  • Matteo Bonini Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Italy.
  • Paolo Palange | paolo.palange@uniroma1.it Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Italy.

Abstract

The case of a 66-year-old man with severe chronic obstructive pulmonary disease (COPD) is presented. Diagnosis was based on baseline pulmonary function tests (PFTs) and clinical examination. Therapy with tiotropium 18 μg (once daily) and salmeterol/fluticasone 50/500 μg (twice daily) failed to achieve optimal disease control. Roflumilast (Daxas) 500 μg once daily was therefore added and a progressive improvement in the patient’s condition was observed during the 1-year followup. In this patient with severe COPD, roflumilast represented a safe and effective therapeutic strategy for managing clinical symptoms and for significantly improving lung function parameters.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2015-08-19
Keywords:
Roflumilast, COPD, Case report, Lung function
Statistics
  • Abstract views: 467

  • PDF: 450
How to Cite
Bonini, Matteo, and Paolo Palange. 2015. “Roflumilast Is Safe and Effective in Improving Symptoms and Lung Function in Severe COPD”. Monaldi Archives for Chest Disease 79 (3-4). https://doi.org/10.4081/monaldi.2013.28.